Online inquiry

IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ477MR)

This product GTTS-WQ477MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ477MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11987MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MM-121
GTTS-WQ2108MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ6438MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ6314MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CS-1008
GTTS-WQ11908MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ7515MR IVTScrip™ mRNA-Anti-HBV, GC-1102(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GC-1102
GTTS-WQ11710MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ14801MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-70
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW